Mode
Text Size
Log in / Sign up

Clinical Trial Search

Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.

Phase
Intervention
Population
Results posted

30 closest matches · ranked by relevance

Phase 2 N=15 Permeability Factor in Focal Segmental Glomerulosclerosis

Focal Segmental Glomerulosclerosis
Primary: Reduction in Proteinuria in Recurrent FSGS Following Renal Transplant With Plasma Exchange and Cyclophosphamide. — 0; 0; 0.5; 0.25 proportion of participants with…
National Institute of Diabetes and Digestive and… Results Feb 2016 20.0% serious AE View details

Phase 2 N=12 Podocyte Retinoids

Collapsing Glomerulopathy · Glomerulosclerosis, Focal Segmental
Primary: Change in Proteinuria at Week 24 From Baseline — 8.42; 7.67 g/g
National Institute of Diabetes and Digestive and… Results Dec 2017 0.0% serious AE View details

N/A N=20 Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis

Light Chain Deposition Disease (LCDD or MIDD) · Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD) · Monoclonal Immunoglobulin Deposition Disease (MIDD)
Primary: Percentage of Participants Experiencing Progression Free Survival at 12 Months — 84 percentage of patients
Memorial Sloan Kettering Cancer Center Results Mar 2020 90.0% serious AE View details

Phase 3 N=8 Steroid Treatment for Kidney Disease

Nephrosis · Focal Lipoid Glomerulosclerosis
Primary: Remission Status of Patients After Intermittent Oral Dexamethasone Administered Over 48 Weeks — 1; 1; 2; 1 participants — p=0.9074
National Institute of Diabetes and Digestive and… Results Oct 2011 37.5% serious AE View details

Phase 2 N=599 A Phase 2b Diabetic Kidney Disease Study

Diabetic Kidney Disease
Primary: Percent Change From Baseline to Day 169 (Week 24) in UACR - Per Protocol Population — -14.82; -17.25; -31.45; -29.70 Percentage change from baseline — p=0.8338
AstraZeneca Results Jul 2024 10.2% serious AE View details